Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | PTGFR | P43088 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8536549 | 0.99 | CYP19A1 (0.58) | CYP19A1KDM4ELMNAPOLBMAPT | |
| SCHEMBL8531854 | 0.95 | CYP19A1 (0.60) | CYP19A1KDM4ELMNAPOLBMAPT | |
| SCHEMBL8535560 | 0.91 | CYP19A1 (0.62) | CYP19A1KDM4ELMNAPOLBMAPT | |
| SCHEMBL7226512 | 0.87 | KDM4E (0.53) | CYP19A1KDM4ELMNAPOLBMAPT | |
| SCHEMBL7169964 | 0.83 | CYP19A1 (0.50) | CYP19A1KDM4ELMNAPOLBMAPT | |
| SCHEMBL9343214 | 0.83 | CYP19A1 (0.61) | CYP19A1KDM4ELMNAPOLBMAPT | |
| SCHEMBL8531164 | 0.83 | CYP19A1 (0.49) | CYP19A1KDM4ELMNAPOLBMAPT | |
| SCHEMBL8672738 | 0.81 | CYP19A1 (0.57) | CYP19A1KDM4ELMNAPOLBMAPT | |
| SCHEMBL8672736 | 0.81 | CYP19A1 (0.57) | CYP19A1KDM4ELMNAPOLBMAPT | |
| SCHEMBL8535701 | 0.81 | CYP19A1 (0.51) | CYP19A1KDM4ELMNAPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1349830-A1 | TETRALONE DERIVATIVES AS ANTITUMOR AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-08 | — | — | EP | disclosed |
| US-6531472-B2 | Has histone deacetylase (HDAC) inhibitory activity which is useful in cancer treatment | HOFFMAN-LA ROCHE INC. | 2003-03-11 | — | — | US | disclosed |
| WO-2002046144-A1 | TETRALONE DERIVATIVES AS ANTITUMOR AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-13 | — | — | WO | disclosed |
| US-20020065282-A1 | Tetralone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2002-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065282-A1 | Tetralone derivatives | HDAC1, HDAC5, HDAC3 | CYP19A1 717/4885KDM4E 112/4885LMNA 839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.